AstraZeneca plc (AZN) Rating Reiterated by Bryan, Garnier & Co

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by stock analysts at Bryan, Garnier & Co in a report issued on Monday. They presently have a GBX 5,220 ($63.62) price objective on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s price objective suggests a potential upside of 4.36% from the stock’s previous close.

AZN has been the topic of a number of other reports. Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 5,800 ($70.69) target price on shares of AstraZeneca plc in a report on Friday, July 29th. Berenberg Bank set a GBX 5,550 ($67.64) target price on AstraZeneca plc and gave the stock a “buy” rating in a report on Thursday, August 25th. Citigroup Inc. reissued a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, July 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($48.75) price target on AstraZeneca plc and gave the stock a “sell” rating in a research note on Wednesday, August 10th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of AstraZeneca plc in a research note on Friday, July 29th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca plc presently has a consensus rating of “Hold” and an average price target of GBX 4,960.13 ($60.45).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 4964.00 on Monday. The company has a 50-day moving average of GBX 4,996.12 and a 200 day moving average of GBX 4,492.93. The stock’s market cap is GBX 62.79 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.